Lexaria Bioscience (LEXX) Profit After Tax (2017 - 2026)

Lexaria Bioscience has reported Profit After Tax for 10 years, with the latest figure at -$2.0 million in Q2 2026.

• Quarterly Profit After Tax rose 47.4% year-over-year to -$2.0 million in Q2 2026, while the trailing twelve-month figure through May 2026 was -$7.8 million (up 31.74% YoY) and the FY2025 annual result came in at -$12.0 million, down 105.77% from the prior year.
• Profit After Tax fell to -$2.0 million in Q2 2026 per LEXX's latest filing, from -$1.4 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$649539.0 in Q1 2024 and troughed at -$3.8 million in Q2 2025.
• A 5-year average of -$1.9 million and a median of -$1.8 million in 2022 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax soared 49.96% in 2024, then sank 317.71% in 2025.
• Over 5 years, Profit After Tax stood at -$1.8 million in 2022, then soared by 32.84% to -$1.2 million in 2023, then plunged by 129.26% to -$2.7 million in 2024, then jumped by 41.01% to -$1.6 million in 2025, then retreated by 24.95% to -$2.0 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$2.0 million, -$1.4 million, and -$1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.